[go: up one dir, main page]

FR2977162B1 - Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic - Google Patents

Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic

Info

Publication number
FR2977162B1
FR2977162B1 FR1155761A FR1155761A FR2977162B1 FR 2977162 B1 FR2977162 B1 FR 2977162B1 FR 1155761 A FR1155761 A FR 1155761A FR 1155761 A FR1155761 A FR 1155761A FR 2977162 B1 FR2977162 B1 FR 2977162B1
Authority
FR
France
Prior art keywords
nanovectors
medicament
polymer particles
diagnostic agent
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1155761A
Other languages
English (en)
Other versions
FR2977162A1 (fr
Inventor
Philippe Bertrand
Regis Delatouche
Valerie Heroguez
Floraine Collette
Marc Gregoire
Christophe Blanquart
Fabien Gueugnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1155761A priority Critical patent/FR2977162B1/fr
Priority to PCT/FR2012/051498 priority patent/WO2013001244A1/fr
Priority to EP12738551.6A priority patent/EP2726107A1/fr
Priority to US14/129,164 priority patent/US20140219925A1/en
Publication of FR2977162A1 publication Critical patent/FR2977162A1/fr
Application granted granted Critical
Publication of FR2977162B1 publication Critical patent/FR2977162B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039Coumarin dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR1155761A 2011-06-28 2011-06-28 Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic Active FR2977162B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1155761A FR2977162B1 (fr) 2011-06-28 2011-06-28 Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic
PCT/FR2012/051498 WO2013001244A1 (fr) 2011-06-28 2012-06-28 Nano vecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic
EP12738551.6A EP2726107A1 (fr) 2011-06-28 2012-06-28 Nano vecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic
US14/129,164 US20140219925A1 (en) 2011-06-28 2012-06-28 Polymer particles or nano-vectors and use thereof as a drug and/or diagnostic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1155761A FR2977162B1 (fr) 2011-06-28 2011-06-28 Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic

Publications (2)

Publication Number Publication Date
FR2977162A1 FR2977162A1 (fr) 2013-01-04
FR2977162B1 true FR2977162B1 (fr) 2013-07-12

Family

ID=46579212

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1155761A Active FR2977162B1 (fr) 2011-06-28 2011-06-28 Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic

Country Status (4)

Country Link
US (1) US20140219925A1 (fr)
EP (1) EP2726107A1 (fr)
FR (1) FR2977162B1 (fr)
WO (1) WO2013001244A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034538A1 (fr) * 2014-12-18 2016-06-22 Universite De Bordeaux Particules de polymère et biomatériaux les contenant
US20170360947A1 (en) * 2014-12-18 2017-12-21 Universite de Bordeaux Polymer particles and biomaterials comprising the same
AU2019285085B2 (en) 2018-06-15 2024-04-18 KWS SAAT SE & Co. KGaA Methods for improving genome engineering and regeneration in plant II
CN112567042B (zh) * 2018-06-15 2024-10-29 科沃施种子欧洲股份两合公司 增强基因组工程化效率的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663469A4 (fr) * 2003-09-05 2009-01-07 Univ Massachusetts Capsules polymeres amphiphiles et procedes associes d'assemblage interfacial
FR2871803B1 (fr) * 2004-06-21 2007-05-11 Centre Nat Rech Scient Cnrse Particules polymeres stimulables presentant des fonctions reactives, leur procede d'obtention, et leurs utilisations
CA2650035C (fr) * 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly(ethylene glycol) contenant des endogroupes chimiquement disparates
CA2662520A1 (fr) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Conjugues polymeres contenant des fragments charges positivement

Also Published As

Publication number Publication date
EP2726107A1 (fr) 2014-05-07
WO2013001244A1 (fr) 2013-01-03
FR2977162A1 (fr) 2013-01-04
US20140219925A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
FR21C1035I2 (fr) Esters arylalcoyles de 4-aminopicolinates et leur utilisation comme herbicides
SG11201408545RA (en) Polymer particles and use thereof
ZA201405501B (en) External files for distribution of molecular diagnostic tests and determination of compatibility between tests
EP2934606A4 (fr) Unités, systèmes et procédés de stérilisation
EP2912438A4 (fr) Systèmes et procédés de diagnostic de santé
EP2912178A4 (fr) Super-activateurs et procédés d'utilisation de ceux-ci
EP2901151A4 (fr) Dispositifs et procédés de diagnostic
EP2920319A4 (fr) Enzymes spécifiques de site et procédés d'utilisation associés
EP2714777A4 (fr) Polymère hydrogel à base de polysaccharide et ses utilisations
IL231514A0 (en) A molecular diagnostic discriminator and method for use
EP2608767A4 (fr) Compositions polymères et procédés associés
EP2837641A4 (fr) Polymère superabsorbant
FR2997406B1 (fr) Polymere de hyaluronate et de glucomannane
EP2842945A4 (fr) Dérivé de sulfonamide et utilisation médicale associée
EP2714817A4 (fr) Particules polymères
EP2833879A4 (fr) Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
EP2915803A4 (fr) Composition de polyisocyanate et composition de polymères d'isocyanate
HRP20171395T1 (hr) Koncentrirane polimerne mješavine vinilaromatskih polimera i/ili vinilaromatskih kopolimera
EP2809510A4 (fr) Points de polymère revêtus de polyélectrolytes et procédés associés
FR2999920B1 (fr) Polymeres a empreinte moleculaire de type solgel et leur utilisation comme agent antipelliculaire
PT2601951E (pt) Composição farmacêutica para o tratamento de hemorragia causada pelo distúrbio da coagulação sanguínea e sua utilização
EP2920588A4 (fr) Particules traceuses et procédés de fabrication de celles-ci
EP2736519A4 (fr) Compositions alcalines et leur utilisation dentaire et médicale
PL2582733T3 (pl) Polimery z bocznymi grupami sacharydowymi i ich zastosowanie
SG11201502786TA (en) Polymers having orthogonal reactive groups and uses thereof

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7